ethylbutyl phenyl sulfone | 74963-79-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethylbutyl phenyl sulfone
• 英文别名: 3-phenylsulfonylhexane；Hexan-3-ylsulfonylbenzene
• CAS: 74963-79-4
• 化学式: C₁₂H₁₈O₂S
• 分子量: 226.34
• InChiKey: NRXTWMZQBMMUNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯亚磺酸 、 alkaline earth salt of/the/ methylsulfuric acid 在 三乙胺 作用下， 生成 ethylbutyl phenyl sulfone
  参考文献：
  名称：

  Champagne, Philippe J.; Renaud, Roger N., Canadian Journal of Chemistry, 1980, vol. 58, p. 1101 - 1105

  摘要：

  DOI：

文献信息

• PYRIDINE-3-CARBOXYAMIDE DERIVATIVE
  申请人：Kitamura Takahiro

  公开号：US20110237590A1

  公开（公告）日：2011-09-29

  To provide a novel JAK3 inhibitor that is useful as a preventive and/or therapeutic agent for rejection and graft versus host disease (GvHD) in organ transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjögren syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic rhinitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia and the like. The pyridine-3-carboxyamide derivative represented by the general formula (1): or its salt or a solvate thereof.

  提供一种新型JAK3抑制剂，可用作器官移植中的预防和/或治疗剂，以及风湿性关节炎、多发性硬化、系统性红斑狼疮、干燥综合征、贝赫切特病、I型糖尿病、自身免疫性甲状腺炎、特发性血小板减少性紫癜、溃疡性结肠炎、克罗恩病、哮喘、过敏性鼻炎、特应性皮炎、接触性皮炎、荨麻疹、湿疹、牛皮癣、过敏性结膜炎、葡萄膜炎、白血病等疾病的预防和治疗。通式（1）所代表的吡啶-3-羧酰胺衍生物： 或其盐或溶剂化合物。
• Amine templated open-framework vanadium(iii) phosphites with catalytic properties
  作者：Joseba Orive、Edurne S. Larrea、Roberto Fernández de Luis、Marta Iglesias、José L. Mesa、Teófilo Rojo、María I. Arriortua

  DOI：10.1039/c2dt32286b

  日期：——

  Four novel amine templated open-framework vanadium(III) phosphites with the formula (C5N2H14)0.5[V(H2O)(HPO3)2], 1 (C5N2H14 = 2-methylpiperazinium), and (L)4−x(H3O)x[V9(H2O)6(HPO3)14−y(HPO4)y(H2PO3)3−z(H2PO4)z]·nH2O (2, L = cyclopentylammonium, x = 0, y = 3.5, z = 3, n = 0; 3, L = cyclohexylammonium, x = 1, y = 0, z = 0.6, n = 2.33; 4, L = cycloheptylammonium, x = 1, y = 0, z = 0, n = 2.33) were synthesized employing solvothermal reactions and characterized by single-crystal X-ray diffraction, ICP-AES and elemental analyses, thermogravimetric and thermodiffractometric analyses, and IR and UV/vis spectroscopy. Single-crystal data indicate that 1 crystallizes in the triclinic system, space group P, whereas 2, 3 and 4 crystallize in the hexagonal space group P63/m. Compound 1 has a two-dimensional motif with anionic sheets of [V(H2O)(HPO3)2]− formula, whose charge is compensated by the 2-methylpiperazinium cations embedded between the layers. In contrast, 2, 3 and 4 present a pillar-layer network giving rise to a three-dimensional framework containing intersecting 16-ring channels with the primary amine templates and the crystallization water molecules enclosed in them. 1, 2, 3 and 4 behave as heterogeneous catalysts for the selective oxidation of alkyl aryl sulfides, with tert-butylhydroperoxide (TBHP) as the oxidizing agent, being active, selective and recyclable for several successive cycles of reaction.

  四种新型胺模板开放框架钒(III)次膦酸盐,其化学式为(C5N2H14)0.5[V(H2O)(HPO3)2],1 (C5N2H14 = 2-甲基哌嗪镎),以及(L)4−x(H3O)x[V9(H2O)6(HPO3)14−y(HPO4)y(H2PO3)3−z(H2PO4)z]·nH2O (2, L = 环戊基铵, x = 0, y = 3.5, z = 3, n = 0; 3, L = 环己基铵, x = 1, y = 0, z = 0.6, n = 2.33; 4, L = 环庚基铵, x = 1, y = 0, z = 0, n = 2.33),通过溶剂热反应合成并用单晶X射线衍射、ICP-AES和元素分析、热重和热差分析以及IR和UV/vis光谱进行了表征。单晶数据显示,1为三斜晶系,空间群P,而2、3和4为六方晶系,空间群P63/m。化合物1具有二维结构,含有[V(H2O)(HPO3)2]−阴离子层,其电荷由嵌入层间的2-甲基哌嗪镎阳离子补偿。相反,2、3和4呈现柱层网络,形成三维框架,包含相交的16元环通道,通道内含有主要胺模板和结晶水分子。1、2、3和4作为非均相催化剂,用于选择性氧化烷基芳基硫醚,以叔丁基过氧化氢(TBHP)为氧化剂,活性高,选择性好,可循环使用多次反应循环。
• Carbostyril derivatives
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0382185A2

  公开（公告）日：1990-08-16

  Novel carbostyril derivatives of the formula: wherein R1 is H, N02, alkoxy, alkoxycarbonyl, alkyl, halogen, optionally substituted amino, OH, CN, COOH, alkanoyloxy, hydrazinocarbonyl; q is 1 to 3, and R is a group of the formula: [wherein R2 is H, alkoxycarbonyl, optionally substituted phenoxycarbonyl, phenylalkenyl-CO-, optionally substituted phenylalkanoyl, alkanoyl, alkenyl-CO-, optionally substituted phenyl-S02-, -CONR8R9, optionally substituted heterocyclic group-CO-, naphthyl-CO-, thienylalkanoyl, tricyclo[3.3.1.1]alkanoyl, (R13 is OH, optionally substituted alkoxy, -NR32R33, -O-A-(E)ℓ-NR4R5, -(B)ℓ-NR6R7, etc.), n is 1 or 2, m is 0 or 1 to 3, R3 is alkyl, R10 is -(CO)ℓ-NR11R12], and the bond between 3- and 4-position of carbostyril nucleus is single or double bond, which have excellent vasopressin antagonistic activities and are useful as vasodilator, hypotensive agent, water diuretics, platelet agglutination inhibitor, and a vasopressin antagonistic composition containing the compound as the active ingredient.

  式中的新型碳四吡啶衍生物： 其中 R1 是 H、N02、烷氧基、烷氧羰基、烷基、卤素、任选取代的氨基、OH、CN、COOH、烷酰氧基、肼基；q 是 1 至 3，R 是式中的基团： [其中 R2 是 H、烷氧基羰基、任选取代的苯氧基羰基、苯基烯基-CO-、任选取代的苯基烷酰基、烷酰基、烯基-CO-、任选取代的苯基-S02-、-CONR8R9、任选取代的杂环基团-CO-、萘基-CO-、噻吩基烷酰基、三环[3.3.1.1]烷酰基、 (R13 为 OH、任选取代的烷氧基、-NR32R33、-O-A-(E)ℓ-NR4R5、-(B)ℓ-NR6R7 等）、 n 为 1 或 2，m 为 0 或 1 至 3，R3 为烷基，R10 为-(CO)ℓ-NR11R12]，碳四吡啶核的 3 位和 4 位之间的键为单键或双键、 这些化合物具有优异的血管加压素拮抗活性，可用作血管扩张剂、降血压剂、利尿剂、血小板凝集抑制剂，以及含有该化合物作为活性成分的血管加压素拮抗组合物。
• Nrf2 Activating Compounds and Uses Thereof
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20210078969A1

  公开（公告）日：2021-03-18

  Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
• US8575153B2
  申请人：——

  公开号：US8575153B2

  公开（公告）日：2013-11-05